Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx.

Levendag, Peter C.; Schmitz, Paul; Jansen, Peter P.; Eijkenboom, W. M. H.; Visser, A.G.; Kolkman-Deurloo, I.K.K.; Sipkema, Dick; Visch, L.L.; Senan, Suresh

doi:10.1200/jco.1998.16.6.2213

Cited by 63 publications

(33 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first database consisted of 151 patients treated for nasopharyngeal carcinoma between 1965À1995. 57 The patients of the second database (n = 110) were treated for an oropharyngeal carcinoma by external radiation therapy (ERT) between 1975À1985 or by the combination of ERT and interstitial radiation therapy (IRT) between 1990À1994. 58 The third database contained all patients (n = 1493) treated in our institution between 1965À1985 for a head and neck malignancy by radiation therapy with curative intent.…”

Section: Methodsmentioning

confidence: 99%

Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors

Wijers¹,

Levendag²,

Braaksma³

et al. 2002

Head & Neck

183

106

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors

Wijers¹,

Levendag²,

Braaksma³

et al. 2002

Head & Neck

183

106

View full text Add to dashboard Cite

show abstract

“…Several retrospective analyses have addressed the role of a brachytherapy boost in nasopharyngeal carcinoma [12][13][14][15][16][17][18]. These studies have looked at brachytherapy as a technique to escalate the dose to the primary tumour and extensions without incurring in unacceptable toxicity to surrounding sensitive organs.…”

Section: Discussionmentioning

confidence: 99%

Brachytherapy Boost in Loco-regionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Trial of the International Atomic Energy Agency

Rosenblatt

El-Gantiry²,

Elattar³

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

AbstactBackground: The purpose was to determine whether a brachytherapy boost improves outcomes in patients with advanced nasopharyngeal carcinoma treated with standard chemo-radiotherapy. Methods:Patients with nasopharyngeal carcinoma WHO grades I-III and TNM stages III or non-metastatic stage IV were eligible for this phase III study. Patients were randomized to either arm (A) induction chemotherapy, followed by external beam radiotherapy (EBRT) with concomitant cisplatin (n = 139) or arm (B), the same schedule plus a brachytherapy boost to the nasopharynx (n = 135). The EBRT doses given were 70 Gy to the primary tumour and positive lymph nodes and 46 Gy to the negative neck. The additional brachytherapy boost in arm (B) was given by either low dose-rate (LDR -11 Gy) or high dose-rate (HDR -3 fractions of 3.0 Gy) brachytherapy. The primary endpoint was 3-year overall survival (OS) and secondary endpoints were: local control, regional control, distant metastasis and grade 3-4 adverse events. Results: 274 patients were randomized between September 2004 and December 2008. The two arms were comparable with regard to age, gender, stage and grade. 273 patients completed treatment. Median follow-up was 29 months (0.2-67 months). The effect of treatment arm, country, age, gender, WHO pathology, stage (T3-4, N2-3 versus other) and chemotherapy on overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS) was studied. Stage significantly affected OS (p = 0.024) and DFS (p = 0.018) while age significantly affected OS (p = 0.014). None of the other factors studied were significant. The 3-year LRFS was 60.5% and 54.4% in arms A and B respectively (p = 0.647). The 3-year regional control rate in the neck was 59.7% and 54.3% respectively (p = 0.7). Distant metastasis developed in 59.7% of patients in arm A and 55.4% in arm B (p = 0.377). Patients with T1/T2 N + had a 3 year LRFS of 51.8% in Arm A (62 patients) versus 57.9% in Arm B (67 patients) (p = 0.343). The grade 3-4 toxicity rate was 21.6% (30/139) and 24.4% (33/135) respectively (p = 0.687).Conclusions: The addition of a brachytherapy boost to external beam radiotherapy and chemotherapy did not improve outcome in loco-regionally advanced nasopharyngeal carcinoma.

show abstract

“…The most common reason for failure is local recurrence that for radiotherapy alone ranges from 15% to 60%, depending on the initial tumor status [14,21,34,36,41].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Integrated Boost (SIB) for Nasopharynx Cancer with Helical Tomotherapy

et al. 2007

View full text Add to dashboard Cite

show abstract

Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx.

Cited by 63 publications

References 55 publications

Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors

Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors

Brachytherapy Boost in Loco-regionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Trial of the International Atomic Energy Agency

Simultaneous Integrated Boost (SIB) for Nasopharynx Cancer with Helical Tomotherapy

Contact Info

Product

Resources

About